15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $825M | -$366M | 69.9% | -47.0% | — | $120M | $150M |
| 2024 | $838M | -$127M | 69.9% | -14.7% | — | $40M | $102M |
| 2023 | $753M | -$263M | 68.6% | -34.2% | — | $39M | $132M |
| 2022 | $678M | -$112M | 70.2% | -20.7% | -$152M | $0 | $57M |
| 2021 | $691M | -$27M | 0.0% | -27.6% | $600000 | $0 | $257M |
| 2020 | $557M | -$224M | 0.0% | -52.0% | — | $225M | $117M |
| 2020 | $639M | -$200M | 0.0% | -36.3% | $51M | $224M | $164M |
| 2019 | $851M | $5M | 0.0% | 0.9% | $75M | $234M | $93M |
| 2018 | $744M | $133M | 0.0% | 16.4% | $108M | $9M | $111M |
| 2017 | $729M | $17M | 0.0% | 6.0% | $100M | $99M | $102M |
| 2016 | $741M | $117M | 0.0% | 20.7% | $161M | — | $69M |
| 2015 | $723M | $80M | 0.0% | 18.5% | — | — | $64M |
| 2014 | — | $176M | — | — | — | — | $65M |
| 2013 | — | $147M | — | — | $162M | — | $104M |
| 2012 | — | $112M | — | — | $132M | — | $86M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $200M | -$34M | 68.7% | -15.3% | — | $120M | $124M |
| Dec '25 | $210M | -$8M | 70.0% | -2.7% | — | $120M | $150M |
| Sep '25 | $206M | -$27M | 69.9% | -11.3% | — | $120M | $145M |
| Jun '25 | $213M | -$331M | 71.2% | -154.5% | — | $59M | $74M |
| Mar '25 | $196M | -$100000 | 68.5% | -14.8% | — | $59M | $92M |
| Dec '24 | $211M | -$43M | 71.7% | -18.5% | — | $40M | $102M |
| Sep '24 | $213M | -$22M | 70.2% | -9.4% | — | $39M | $100M |
| Jun '24 | $212M | -$37M | 69.6% | -17.3% | — | $39M | $92M |
| Mar '24 | $202M | -$26M | 68.1% | -13.8% | — | $39M | $97M |
| Dec '23 | $197M | -$31M | 68.7% | -16.0% | — | $39M | $132M |
| Sep '23 | $192M | -$61M | 70.0% | -31.3% | — | $39M | $76M |
| Jun '23 | $184M | -$116M | 68.5% | -62.0% | -$20M | $38M | $103M |
| Mar '23 | $181M | -$55M | 67.3% | -28.8% | -$57M | $0 | $54M |
| Dec '22 | $178M | -$42M | 0.0% | -29.4% | -$22M | $0 | $57M |
| Sep '22 | $156M | -$35M | 67.8% | -28.8% | -$21M | $0 | $109M |
| Jun '22 | $179M | -$14M | 72.3% | -9.9% | -$56M | $0 | $104M |
| Mar '22 | $165M | -$21M | 70.9% | -15.5% | -$53M | $0 | $164M |
| Dec '21 | $161M | -$8M | 0.0% | -26.8% | -$13M | $0 | $257M |
| Sep '21 | $167M | $25M | 0.0% | -47.8% | -$42M | $0 | $295M |
| Jun '21 | $189M | -$5M | 0.0% | -11.0% | -$9M | $104M | $118M |
How the market has priced MYGN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Myriad Genetics Inc's revenue has grown 5.2% per year. These are computed facts, not advice.
As of FY2025, Myriad Genetics Inc reported $120M of total debt against $150M of cash; operating income covered interest expense -36.9×.
In FY2025, gross margin was 69.9%, operating margin -47.0%, and net margin -44.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.